Breaking News Instant updates and real-time market news.

GILD

Gilead

$67.22

0.31 (0.46%)

, NVS

Novartis

$94.30

4.185 (4.64%)

08:37
07/19/19
07/19
08:37
07/19/19
08:37

Gilead licenses three preclinical antiviral programs from Novartis

Gilead (GILD) announced that it has licensed three preclinical antiviral programs from Novartis (NVS), including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291M in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales.

GILD

Gilead

$67.22

0.31 (0.46%)

NVS

Novartis

$94.30

4.185 (4.64%)

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 30

    Jul

  • 07

    Aug

  • 09

    Sep

  • 25

    Sep

GILD Gilead
$67.22

0.31 (0.46%)

07/15/19
JEFF
07/15/19
NO CHANGE
Target $95
JEFF
Buy
Gilead deal with Galapagos 'smart and financially savvy,' says Jefferies
Gilead Sciences (GILD) will significantly expand its pipeline in a "smart and financially savvy" expanded partnership deal with Galapagos (GLPG), Jefferies analyst Michael Yee tells investors in a research note. Gilead essentially gained options on everything in Galapagos' pipeline without having to acquire the company full out, says the analyst. He likes the deal and thinks shares of Gilead will move higher as the Street's outlook continues to improve. Yee keeps a Buy rating on Gilead with a $95 price target.
07/15/19
STFL
07/15/19
NO CHANGE
Target $188
STFL
Buy
Galapagos price target raised to $188 from $121 at Stifel
Stifel analyst Adam Walsh raised his price target on Galapagos (GLPG) to $188 from $121 after the company announced a 10-year global research and development collaboration with Gilead (GILD), calling the collaboration "a win-win to both companies." The deal, which he thinks will keep Gilead and likely other buyers from acquiring Galapagos in the next 10 years, gives the latter a deep cash position and support to expand and accelerate its research and clinical programs while it is able to maintain its "unique culture, R&D platform and proven leadership," according to Walsh, who keeps a Buy rating on Galapagos shares.
07/15/19
07/15/19
DOWNGRADE

Market Perform
Galapagos downgraded to Market Perform after Gilead deal at Raymond James
As previously reported, Raymond James analyst Dane Leone downgraded Galapagos (GLPG) to Market Perform from Strong Buy after the company and Gilead (GILD) announced a major expansion of the current collaboration agreement and partnership between the two companies. The analyst believes Galapagos' stock has now fully realized his price target by achieving his core investment thesis. He retains a positive viewpoint of Galapagos within the context of the relationship expansion with Gilead, but will be watching for how key 2020 value drivers develop over the course of the second half of 2019.
07/18/19
PIPR
07/18/19
NO CHANGE
Target $10
PIPR
Overweight
Spring Bank research agreement with NIAID 'smart,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Spring Bank (SBPH) entered into a research agreement with the National Institute of Allergy and Infectious Diseases, or NIAID, to study preclinical HBV antisense oligonucleotides. With the recent Arrowhead (ARWR) partnership with Janssen (JNJ), the analyst sees this as a "smart development program" building on Spring Bank's HBV expertise. Tenthoff also notes that Spring Bank is conducting the Phase IIb CATALYST 1 and 2 trials of 400mg inarigivir monotherapy/combination with Vemlidy in naive and suppressed HBV patients with preliminary data in the second quarter of 2020, while partner Gilead (GILD) is conducting a Phase II study of inarigivir plus Vemlidy in naive and suppressed HBV patients with initial data likely at AASLD in November. He reiterates an Overweight rating and $10 price target on Spring Bank's shares.
NVS Novartis
$94.30

4.185 (4.64%)

06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/17/19
RAJA
07/17/19
NO CHANGE
RAJA
Investors shouldn't overreact to drug proposal headlines, says Raymond James
Raymond James analyst Chris Meekins noted that President Donald Trump has indicated an Executive Order on drug pricing is coming soon, but he believes investors "should be cautious not to overreact" to drug related proposal headlines as he "cannot think of a single proposal that was finalized and also survived a court challenge resulting in a negative impact on earnings" yet from the Trump Administration. Given the history of the current White House to date, Meekins said he is increasingly skeptical the Administration will get anything meaningful finalized and overcome legal challenges that will impact drugmakers' earnings before the 2020 election, he tells investors in a healthcare policy note. Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
07/18/19
WELS
07/18/19
NO CHANGE
WELS
Novartis' Sandoz trends a negative for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris said that while Novartis' (NVS) Sandoz Q2 results were better than expected, they were mainly driven by ex-U.S. performance, and the analyst believes this could have "negative implications for other companies with significant U.S. commodity generics, such as Teva (TEVA) and Mylan (MYL) though perhaps moreso for Mylan." Maris noted that on the conference call, Novartis stated, "If you take out one-time, certain one-time effects, you would see that in the U.S. the base business continues to have declines in the mid-teens consistent with what we've seen in past quarters, so we haven't seen yet a stabilization in the core GX business in the U.S." The analyst concluded that the commentary is consistent with his "continued caution on generics."

TODAY'S FREE FLY STORIES

QSR

Restaurant Brands

$74.89

0.36 (0.48%)

09:56
08/19/19
08/19
09:56
08/19/19
09:56
Recommendations
Restaurant Brands analyst commentary  »

SSS at Restaurant…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGNA

Tegna

$15.70

0.62 (4.11%)

, APO

Apollo Global

$34.18

2.15 (6.71%)

09:56
08/19/19
08/19
09:56
08/19/19
09:56
Hot Stocks
Tegna jumps after report of Apollo deal interest »

Shares of Tegna (TGNA)…

TGNA

Tegna

$15.70

0.62 (4.11%)

APO

Apollo Global

$34.18

2.15 (6.71%)

NXST

Nexstar

$96.12

2.07 (2.20%)

TRCO

Tribune Media

$46.48

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 23

    Sep

  • 13

    Nov

EL

Estee Lauder

$193.74

14.48 (8.08%)

, DO

Diamond Offshore

$6.19

0.365 (6.27%)

09:55
08/19/19
08/19
09:55
08/19/19
09:55
Options
Early notable gainers among liquid option names on August 19th »

Notable gainers among…

EL

Estee Lauder

$193.74

14.48 (8.08%)

DO

Diamond Offshore

$6.19

0.365 (6.27%)

NVDA

Nvidia

$166.49

7.01 (4.40%)

WYNN

Wynn Resorts

$109.82

4.24 (4.02%)

TGNA

Tegna

$15.61

0.53 (3.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 27

    Aug

  • 05

    Sep

  • 09

    Sep

  • 23

    Sep

PCG

PG&E

$11.12

-3.18 (-22.24%)

09:52
08/19/19
08/19
09:52
08/19/19
09:52
Downgrade
PG&E rating change  »

Citi double downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$31.70

-2.48 (-7.26%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF falls -7.2% »

ProShares Trust Ultra VIX…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$71.82

-6.26 (-8.02%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
Direxion Daily Jr Gld Mnrs Bull 3X Shrs falls -7.9% »

Direxion Daily Jr Gld…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$10.40

-3.9 (-27.27%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
PG&E falls -27.3% »

PG&E is down -27.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$198.05

18.785 (10.48%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
Estee Lauder rises 10.4% »

Estee Lauder is up 10.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

TGNA

Tegna

$16.42

1.34 (8.89%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
Tegna rises 9.4% »

Tegna is up 9.4%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

ARMK

Aramark

$41.24

4.17 (11.25%)

09:47
08/19/19
08/19
09:47
08/19/19
09:47
Hot Stocks
Aramark rises 11.2% »

Aramark is up 11.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$14.30

(0.00%)

09:43
08/19/19
08/19
09:43
08/19/19
09:43
Downgrade
PG&E rating change at Citi »

PG&E downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WB

Weibo

$37.05

(0.00%)

, IQ

iQIYI

$17.08

(0.00%)

09:40
08/19/19
08/19
09:40
08/19/19
09:40
Options
Unusually active option classes on open August 19th »

Unusual total active…

WB

Weibo

$37.05

(0.00%)

IQ

iQIYI

$17.08

(0.00%)

LYFT

Lyft

$52.37

(0.00%)

XLU

Utilities SPDR

$61.35

(0.00%)

UAL

United Continental

$82.96

(0.00%)

WYNN

Wynn Resorts

$105.58

(0.00%)

EA

Electronic Arts

$89.56

(0.00%)

DB

Deutsche Bank

$6.95

(0.00%)

NVDA

Nvidia

$159.48

(0.00%)

MSFT

Microsoft

$136.13

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

  • 19

    Aug

  • 19

    Aug

  • 20

    Aug

  • 04

    Sep

  • 04

    Sep

  • 05

    Sep

  • 09

    Sep

  • 10

    Sep

  • 23

    Sep

  • 27

    Oct

  • 13

    Nov

OMCL

Omnicell

$70.48

0.475 (0.68%)

09:38
08/19/19
08/19
09:38
08/19/19
09:38
Conference/Events
Omnicell management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

CHU

China Unicom

$9.93

0.155 (1.59%)

09:35
08/19/19
08/19
09:35
08/19/19
09:35
Downgrade
China Unicom rating change at New Street »

China Unicom downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:35
08/19/19
08/19
09:35
08/19/19
09:35
General news
FX Action: USD-CAD »

FX Action: USD-CAD pulled…

REDU

Rise Education

$7.88

-0.13 (-1.62%)

09:34
08/19/19
08/19
09:34
08/19/19
09:34
Downgrade
Rise Education rating change at Morgan Stanley »

Rise Education downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGNA

Tegna

$15.08

1.465 (10.76%)

09:31
08/19/19
08/19
09:31
08/19/19
09:31
Upgrade
Tegna rating change at Wolfe Research »

Tegna upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

CLNC

Colony Credit Real Estate

$13.04

0.165 (1.28%)

09:31
08/19/19
08/19
09:31
08/19/19
09:31
Recommendations
Colony Credit Real Estate analyst commentary at Raymond James »

Colony Credit Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$80.84

1.67 (2.11%)

09:30
08/19/19
08/19
09:30
08/19/19
09:30
Downgrade
Zscaler rating change at OTR Global »

Zscaler downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 10

    Oct

  • 15

    Oct

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

, LGF.B

Lionsgate

$10.52

0.01 (0.10%)

09:30
08/19/19
08/19
09:30
08/19/19
09:30
Upgrade
Lionsgate, Lionsgate rating change  »

Lionsgate upgraded to…

LGF.A

Lionsgate

$11.06

0.02 (0.18%)

LGF.B

Lionsgate

$10.52

0.01 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PANW

Palo Alto Networks

$199.26

-15.5 (-7.22%)

09:29
08/19/19
08/19
09:29
08/19/19
09:29
Recommendations
Palo Alto Networks analyst commentary  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 10

    Oct

  • 15

    Oct

PULM

Pulmatrix

$0.82

0.0076 (0.94%)

09:28
08/19/19
08/19
09:28
08/19/19
09:28
Hot Stocks
Pulmatrix receives U.S. patent covering iSPERSE formulations »

Pulmatrix has received a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

MMSI

Merit Medical

$36.17

-0.67 (-1.82%)

09:27
08/19/19
08/19
09:27
08/19/19
09:27
Hot Stocks
Merit Medical appoints Lynne Ward to board of directors »

Merit Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

VMW

VMware

$143.67

1.13 (0.79%)

, AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

09:27
08/19/19
08/19
09:27
08/19/19
09:27
Recommendations
VMware, Amazon.com, Microsoft analyst commentary at RBC Capital »

VMware to deliver…

VMW

VMware

$143.67

1.13 (0.79%)

AMZN

Amazon.com

$1,791.82

16.72 (0.94%)

MSFT

Microsoft

$136.13

2.39 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 04

    Sep

  • 10

    Sep

  • 10

    Oct

  • 27

    Oct

VCEL

Vericel

$16.31

0.705 (4.52%)

09:25
08/19/19
08/19
09:25
08/19/19
09:25
Conference/Events
Vericel participates in a conference call with SVB Leerink »

SVB Leerink to host a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.